EPLAW PATENT BLOG

NL – Sandoz v. AstraZeneca / invalidity

Posted: April 12th, 2018

Sandoz B.V. v. AstraZeneca AB, District Court The Hague, 11 April 2018, Case No. ECLI:NL:RBDHA:2018:4127 Contrary to earlier PI infringement proceedings, which were confirmed on appeal earlier (see here), the Court in invalidity proceedings instigated by Sandoz ruled that AstraZeneca’s  patent relating to a Fulvestrant formulation marketed under the name FASLODEX® which is used for […]

READ MORE

ES – FRACTUS v. WIKO / Preliminary injunction / Mobile World Congress IP Fast Action Protocol

Posted: April 5th, 2018

Fractus S.A. v. Wikomobile Iberia S.L., Barcelona Commercial Court No. 5, 16 February 2018, Docket No. 4/2018 In the context of the IP Fast Action Protocol adopted for the 2018 Mobile World Congress (see more information here), the Spanish company FRACTUS, owner of several patents related to antenna technology for wireless devices, filed an inter […]

READ MORE

NL – Coloplast v. Medical4You / Appeal

Posted: March 30th, 2018

Coloplast holds EP ‘729 for a ‘ready-to-use urine catheter assembly’. The package according to the patent is a so called ‘wet package’. Contrary to the Technical Board of Appeal, the Court of Appeal rules that a catheter in a ‘wet package’ is not inventive. The Court of Appeal further states that once put on the […]

READ MORE

NL – ICOS v. Teva, Sandoz and Mylan

Posted: March 29th, 2018

ICOS Corporation v. Teva Nederland B.V., ICOS Corporation v. Sandoz B.V., ICOS Corporation v. Mylan B.V., Interlocutory Decisions Judge of the District Court The Hague, 28 March 2018, Case no. ECLI:NL:RBDHA:2018:3456 Three PI proceedings. Main proceedings were stayed earlier. Preliminary injunctions based on Tadalafil patent now denied, since the patent was meanwhile revoked due to […]

READ MORE

NL – Teva v. Icos / Tadalafil (Cialis®)

Posted: March 15th, 2018

Teva Pharmaceuticals Europe B.V. v. Icos Corporation, District Court The Hague, The Netherlands, 14 March 2018, Case No. ECLI:NL:RBDHA:2018:2668 Icos (an Eli Lilly and Company subsidiary) holds EP 1 173 181 B3 (‘EP 181’) entitled: ‘Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction.’  Teva seeks to revoke the Dutch part of EP 181. […]

READ MORE

UK – CANTEL V. ARC

Posted: March 9th, 2018

Cantel Medical (UK) Ltd and Cantel (UK) Limited v Arc Medical Design Limited [2018] EWHC 345 (Pat), UK Patents Court, Hacon J In order to clear the path to market for its AmplifEYE endoscopic device, Cantel sought revocation and declarations of non-infringement of Arc’s UK national and European patents relating to Arc’s Endocuff and Endocuff […]

READ MORE

SE – Sandoz v. ViiV Healthcare

Posted: March 2nd, 2018

Sandoz A/S v. ViiV Healthcare UK Limited, Patent and Market Court of Appeal, Sweden, 30 June 2017, Docket No. PMÖ 3565-17 Sandoz requested that the preliminary injunction barring its pharmaceutical products Abacavir/Limavudine Sandoz 600 mg/300 mg from being marketed and sold on the Swedish market be vacated. The Patent and Market Court of Appeal overturned […]

READ MORE

NL – Ono v. Pfizer

Posted: March 1st, 2018

Ono Pharmaceutical Co. Limited v. Pfizer Inc., Interlocutory Judge District Court The Hague, 27 February 2018, Case no. ECLI:NL:RBDHA:2018:2284 Ono filed a European patent application EP ‘517 A1 entitled: ‘Immunopotentiating compositions comprising anti-PD-L1 antibodies’. After the rejection of Pfizer’s third party observations at the EPO, Pfizer lodged proceedings at the German Verwaltungsgericht in Munich claiming […]

READ MORE

NL – Celltrion v. Biogen / English translation

Posted: February 28th, 2018

Celltrion Inc. v. Biogen Inc., District Court The Hague, 21 February 2018, now including an English translation, with thanks to Daan van der Lange, Jan Pot and Boukje van der Maazen, Brinkhof Biogen holds EP 2055313  that relates to a ‘Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody’. Celltrion instigated invalidity […]

READ MORE

NL – LEO Pharma v. Sandoz

Posted: February 21st, 2018

LEO Pharma A/S v. Sandoz, Court of Appeal of The Hague, the Netherlands, 7 November 2017, published 12 February 2018, Case no. ECLI:NL:GHDHA:2017:4029 LEO Pharma is the holder of the European patent EP 2 455 083 B1 titled “Pharmaceutical composition for dermal use comprising calcipotriol and betamethasone for treating psoriasis”. The patent was granted on […]

READ MORE